

Radiation Therapy Contouring: Cardiac/Thoracic Anatomy

Mary Feng, M.D.

Department of Radiation Oncology University of Michigan



- **Targets:** Tumors and Nodal stations
- <u>Normal tissues</u>:
 - Reduce doses by blocking
 - Choosing beam angles with greatest separation between targets and OARs
 - Understanding dose-volume-toxicity relationships
 - Reducing toxicity



- 1) Understand the need for consistency in normal tissue contouring in the thorax
- 2) Be able to access atlases developed by radiation oncologists to improve contour consistency
- 3) Use these atlases as a guide to standardize contours and improve normal tissue sparing



- Heart
- Brachial plexus
- Esophagus



The NEW	ENGLAND		
JOURNAL	of MEDICINE		

ESTABLISHED IN 1812

MARCH 14, 2013

VOL. 368 NO. 11

Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

Sarah C. Darby, Ph.D., Marianne Ewertz, D.M.Sc., Paul McGale, Ph.D., Anna M. Bennet, Ph.D., Ulla Blom-Goldman, M.D., Dorthe Brønnum, R.N., Candace Correa, M.D., David Cutter, F.R.C.R., Giovanna Gagliardi, Ph.D., Bruna Gigante, Ph.D., Maj-Britt Jensen, M.Sc., Andrew Nisbet, Ph.D., Richard Peto, F.R.S., Kazem Rahimi, D.M., Carolyn Taylor, D.Phil., and Per Hall, Ph.D.

(Reuters Health) - The radiation that might cure a breast cancer may also raise a woman's risk of having a heart attack or heart disease later in life, according a new study that looked back at the cases of 2,168 women in Sweden and Denmark



METHODS

We conducted a population-based case–control study of major coronary events (i.e., myocardial infarction, coronary revascularization, or death from ischemic heart disease) in <u>2168 women</u> who underwent radiotherapy for breast cancer between <u>1958 and 2001</u> in Sweden and Denmark; the study included 963 women with major coronary events and 1205 controls. Individual patient information was obtained from hospital records. For each woman, the mean radiation doses to the whole heart and to the left anterior descending coronary artery were estimated from her radio-therapy chart.

RESULTS

The overall average of the mean doses to the whole heart was 4.9 Gy (range, 0.03 to 27.72). Rates of major coronary events increased linearly with the mean dose to the heart by 7.4% per gray (95% confidence interval, 2.9 to 14.5; P<0.001), with no apparent threshold. The increase started within the first 5 years after radiotherapy and continued into the third decade after radiotherapy. The proportional increase in the rate of major coronary events per gray was similar in women with and women without cardiac risk factors at the time of radiotherapy.

Dose effect on the heart

200-Percent Increase in Rate of Major Coronary Events (95% CI) 150-100-No threshold 50--50-Increase per gray, 7.4% (95% CI, 2.9-14.5) P<0.001 -100-10 12 14 16 18 20 8 Mean Dose of Radiation to Heart (Gy)

Radiation Oncology

Medical School

Dose effect on the heart



Medical School



- Virtual simulation and planning based on CT or manual planning "were used to reconstruct each radiotherapy regimen on the CT scan of a woman with typical anatomy"
- (Virtual) Radiation doses to the structures of interest were then estimated
- In manual planning, the (virtual) doses were estimated on the basis of charts on which isodose curves had been drawn



- Dose-volume histograms for the whole heart and for the left anterior descending coronary artery were obtained
- Mean doses were calculated



- In general? Probably
- Specifically? No
 - Reconstructed, hypothesized cardiac doses
 - Not based on reality



The time-course and extent of cardiac damage depends on dose

- In the past, Hodgkin's survivors were diagnosed with heart disease 1-2 years after radiotherapy (30 Gy+)
- Latency greater for lower doses of RT

Cardiac toxicity after breast RT

SEER study of 300,000 women with breast cancer



Darby, et al. Lancet Oncology 2005

University of Michigan Medical School

Rationale for heart avoidance

JOURNAL OF CLINICAL ONCOLOGY A SCO SPECIAL ARTICLE American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects Joseph R. Carver, Churles L. Shupiro, Andrea Ng, Linda Jacoba, Cindy Schwartz, Katherine S. Virgo, Katter L. Hagerts, Mark R. Somerfield, and David I. Vaughn for the ASCO Cancer Survivorship Expert Panel

Structure	Abnormality	Natural History	Pathology
Pericardium	Pericarditis	Chronic asymptomatic effusion and/or pericarditis with symptoms: hemodynamic compromise with either constriction or tampopade	Fibrous thickening and fluid production
Myocardium	Myocarditis	Progressive diastolic dysfunction and restrictive hemodynamics with symptoms: CHF	Diffuse interstitial fibrosis/microcirculatory damage leading to capillary obstruction/extensive fibrosis
Endocardium	Valvular damage	Over time, progressive stenosis and regurgitation	Cusp and/or leaflet fibrosis
Vascular System	Arteritis	Premature CAD/accelerated atherosclerosis	Ostial and proximal stenosis; LAD, RCA, and left main more than left circumflex
		Pulmonary hypertension	Pathology similar to atherosclerosis
Conduction System		All forms of heart block and conduction delay	Fibrosis of the conduction system
Autonomic Dysfunction		Supraventricular tachycardia; heart rate variability	

Medical School



Mechanisms of RT cardiac effects



Figure 1 Pathophysiological manifestations of radiation-induced heart disease for different radiosensitive structures within the heart. LV: left ven tricle; RT: radiotherapy.

Radiation Oncology

Lancelloti, et al. Euro Heart J- Cardio Imaging, 2013.

MF13 15



Pneumonitis

Xerostomia



Kwa et al, IJROBP 1998



Dijkema et al, IJROBP 2010

Radiation Oncology



Rectal Toxicity

Gastric Bleed



Tucker, et al, IJROBP 2012

Feng, et al, IJROBP 2012

Radiation Oncology



Why haven't we had similar plots for cardiac damage?

- In the pre-CT era, we could not accurately define the heart
- There is little agreement on how to define the heart
- Additionally, substructures of the heart may have specific importance



Mean LAD dose

The data is hypothesized

Medical School

Table 3. Cardiac mortality from ischemic heart disease/myocardial infarction: Dose-volume predictors and NTCP parameters					
Authors, Year, Reference	Diagnosis, No. of patients, Years of treatment	OAR	Dose data	Predictive parameters	NTCP parameters
Hancock et al. 1993 (17)	Hodgkin's 2232 patients 1960–1990	Heart	Dose up to 44 Gy Pre-3D dose data	D _{mediastinum} > 30 Gy	
Gagliardi <i>et al</i> . 1996 (25)	Breast 809 patients 1964–1976	Heart*	45–50 Gy [†] 1.8–2.5 Gy/fraction treatments reconstructed in 3D on average natients		RS [‡] (<i>CI</i> 68%) D50 = 52.3 Gy (49;57) $\gamma = 1.28$ (1.04;1.64) s = 1 (0.63; at limit)
Eriksson <i>et al.</i> 2000 [§] (51)	Hodgkin's 157 patients 1972–1985	Heart	~40 Gy 2 Gy/fraction Individual treatments reconstructed in 3D on phantom	D ₃₅ > 38 Gy	RS: Hodgkin's D50 = 70.3 Gy $\gamma = 0.96$ s = 1 RS: Hodgkin's + breast D50 = 63 Gy $\gamma = 0.94$ s = 1
Carr et al. 2005 (52)	Peptic ulcer, 1,859 patients, 1936–1965	Heart (Alderson Phantom)	1.5 Gy /fraction 250-kVp X-rays Treatment simulated on phantom	D_{mean} to 5% >12 Gy heart volume within the beam $D_{mean} > 2.5$ Gy whole heart volume	5 - 1
Paszat <i>et al</i> 2007 (6)	Breast, 619 patients, 1982–1988	Heart	40–50 Gy 2–2.67 Gy/fraction to breast Pre-3D dose data	RT to Internal Mammary Chain	

Radiation Oncology

Gagliardi, et al, QUANTEC, IJROBP 2010.





Gagliardi, et al, QUANTEC, IJROBP 2010.

Radiation Oncology

MF13 20



- We must first understand the relationship between dose and volume of heart (or cardiac substructures) and toxicity
- We can then incorporate these into treatment planning to minimize the risk of cardiac complications



Motivated by the lack of consistency in cardiac delineation, we

- Developed an atlas of cardiac substructure anatomy through a collaboration with cardiology and cardiac radiology
- Validated this atlas using a pre- and posttest study of 7 radiation oncologists





Heart begins just inferior to L pulmonary artery

Non-contrast CT







Non-contrast CT







Feng, et al. IJROBP, 2011

MF13 25





Non-contrast CT







Feng, et al. IJROBP, 2011

MF13 27

















Contrast CT







Contrast CT











Which of these structures is the LAD? A B C D



Multi-observer pre-test and post-test study



Pre-testPost-testFeng, et al. IJROBP, 2011





Pre-test Post-test Feng, et al. IJROBP, 2011



Radiat

Percent overlap of observer and gold standard contours

Structure	Pre-atlas	Post-atlas	p-value
	(mean ±SD)	(mean ±SD)	
Heart	79 ± 13	91 ± 4	<0.001
L main	10 ± 22	22 ± 20	<0.001
LAD	35 ± 21	62 ± 16	<0.001
R coronary	11 ± 14	24 ± 18	0.002
Left ventricle	87 ± 11	92 ± 6	0.06
Right ventricle	65 ± 10 Feng, et	74 ± 8 al. IJROBP, 2011	0.003

13 37



Radiat

Structure	Pre-atlas	Post-atlas	p-value
	(mean ±SD)	(mean ±SD)	
Heart	0.76 ± 0.11	0.89 ± 0.03	<0.001
L main	0.05 ± 0.12	0.18 ± 0.16	<0.001
LAD	0.19 ± 0.11	0.34 ± 0.07	<0.001
R coronary	0.08 ± 0.10	0.18 ± 0.08	<0.001
Left ventricle	0.75 ± 0.06	0.79 ± 0.05	0.04
Right ventricle	0.55 ± 0.08 Feng, et	0.65 ± 0.08 al. IJROBP, 2011	<0.001

13 38



Radiat

Mean absolute value dose difference (Gy)

Structure	Pre-atlas	Post-atlas	p-value
	(mean ±SD)	(mean ±SD)	
Heart	0.88 ± 0.15	0.14 ± 0.14	<0.001
L main	1.68 ± 1.53	0.88 ± 1.56	0.005
LAD	3.90 ± 2.80	2.56 ± 3.31	<0.001
R coronary	1.15 ± 1.07	0.61 ± 0.39	0.001
Left ventricle	0.25 ± 0.20	0.15 ± 0.14	0.13
Right ventricle	1.06 ± 0.73 Feng, et	0.46 ± 0.37 al. IJROBP, 2011	0.008

13 39



- Breast RT may increase the risk of cardiac death many years after treatment
- Unlike other structures such as the parotid gland, lung, and rectum, the heart's dose-volume-toxicity profile is not well-understood
- With a validated, detailed cardiac atlas, we can begin to collect information to elucidate the effect of RT on heart structures



- Heart
- Brachial plexus
- Esophagus



- Heart
- Brachial plexus
- Esophagus



- Brachial plexus damage could lead to arm weakness or pain
- Commonly used dose limits range from 50 to 60 Gy
- Hot spots in treatment plans can be located in the brachial plexus if careful planning is not used

University of Mich igan Medical School







www.healthcare.siemens.com





Hall, et al. IJROBP 2008 and at http://www.rtog.org

Radiation Oncology





Hall, et al. IJROBP 2008 and at http://www.rtog.org

Radiation Oncology





Hall, et al. IJROBP 2008 and at http://www.rtog.org





Hall, et al. IJROBP 2008 and at http://www.rtog.org

Radiation Oncology





Hall, et al. IJROBP 2008 and at http://www.rtog.org

Radiation Oncology

MF13 50



Quiz

Which of these structures Is the brachial plexus? A

B С D





Brachial plexopathy from RT

International Journal of Radiation Oncology biology • physics

www.redjournal.org

Clinical Investigation: Thoracic Cancer

Brachial Plexopathy in Apical Non-Small Cell Lung Cancer Treated With Definitive Radiation: Dosimetric Analysis and Clinical Implications

Michael J. Eblan, MD,* Michael N. Corradetti, MD, PhD,* J. Nicholas Lukens, MD,* Eric Xanthopoulos, MD, JD,* Nandita Mitra, PhD,[†] John P. Christodouleas, MD, MPH,* Surbhi Grover, MD,* Annemarie T. Fernandes, MD,* Corey J. Langer, MD,[‡] Tracey L. Evans, MD,[‡] James Stevenson, MD,[‡] Ramesh Rengan, MD, PhD,* and Smith Apisarnthanarax, MD*

Departments of *Radiation Oncology, [†]Biostatistics and Epidemiology, and [‡]Medical Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

Eblan, et al, IJROBP 2012





Fig. 2. Cumulative rate of RIBP as a function of maximal dose delivered to the IBP.

Eblan, et al, IJROBP 2012

MF13 53



- Heart
- Brachial plexus
- Esophagus



- Heart
- Brachial plexus
- Esophagus



- Can be a significant side effect of RT, especially if combined with chemotherapy for lung cancer
- Pain affects quality of life and causes patients to lose weight, which reduces the ability to tolerate treatment
- Multiple dose-volume limits have been proposed to minimize esophagitis



- RTOG recommends contouring from the cricoid to the GE junction
- Esophageal diameter, shape, and position are variable
- Pay attention for accurate contours



The esophagus starts at the level of cricoid



Kong, et al



Usually it quickly becomes round



Kong, et al



Then it can take a turn to the side



Radiation Oncology

Kong, et al

MF13 60



...and flatten out more...



Kong, et al



... before it rounds out again and joins the stomach.



Kong, et al

University of Michigan Medical School



Kwint, et al, IJROBP 2012

MF13 63





A: Esophagus Contour Variants

Kong, et al, IJROBP 2011



- Accurate OAR contouring is important for treatment planning
- Atlases have been created to improve consistency
- As centers create more uniform OAR contours, data can be compiled to build more realistic models to estimate and minimize toxicity risk

Thanks for your attention University of Michigan Medical School



